[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study SiteCall center
Email address
Condition
Treatment type
Investigational product
Phase
Sponsor
ClinicalTrials.gov identifier
Study number
Get answers to your questions about clinical trials.
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
You may be eligible to participate in the study if you meet the following criteria:
For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study Site